WHAT IS CLAIMED IS:

1. A compound of the formula:



I

or a pharmaceutically acceptable salt or prodrug thereof,

wherein:

n is from 0 to 3;

X is $-CR^aR^b-$ or $-C(O)-$, wherein R^a and R^b each independently are hydrogen or alkyl;

---- is an optional bond;

Y is $-SO_2-$ when X is $-CR^aR^b-$ and Y is $-(CR^cR^d)_p-$ when X is $-C(O)-$, wherein p is from 1 to 3 and R^c and R^d each independently are hydrogen or alkyl;

each R^1 independently is halo, alkyl, haloalkyl, heteroalkyl, hydroxy, nitro, alkoxy, cyano, $-S(O)_q-R^e$, $-NR^eR^f$, $-C(=O)-NR^eR^f$, $-SO_2-NR^eR^f$, $-N(R^e)-C(=O)-R^f$, or $-C(=O)R^e$, wherein q is from 0 to 2 and R^e and R^f each independently are hydrogen or alkyl;

R^2 is aryl, heteroaryl or cycloalkyl;

R^3 and R^4 each independently are hydrogen or alkyl; and

R^5 is at the 5- or 6- position of the isoquinoline ring system and is of the formula:



wherein:

Z is –N– or –CH–;

r is from 1 to 3; and

R^6, R^7, R^8, R^9 and R^{10} each independently are hydrogen or alkyl.

2. The compound of claim 1, wherein R5 is located at the 5- position of the isoquinoline ring system.

3. The compound of claim 2, wherein Z is –N–.

4. The compound of claim 3, wherein X is $-CR^aR^b-$ and Y is $-SO_2-$.

5. The compound of claim 3, wherein X is –C(O)– and Y is $-(CR^cR^d)_p-$.

6. The compound of claim 4, wherein R^a and R^b are hydrogen.

7. The compound of claim 6, wherein R^2 is aryl.

8. The compound of claim 7, wherein R^2 is optionally substituted phenyl.

9. The compound of claim 7, wherein R^2 is optionally substituted naphthalenyl.

10. The compound of claim 7, wherein R^2 is selected from the group consisting of phenyl, 2-halophenyl, 3-halopheny, 4-halophenyl, 2,3-dihalophenyl, 2,4-dihalophenyl, 3,4-dihalophenyl, 2,5-dihalophenyl, 3,5-dihalophenyl, 2,6-dihalophenyl, 2-haloalkylphenyl, 3-haloalkylpheny, 4-haloalkylphenyl, 2,3-dihaloalkylphenyl, 2,4-dihaloalkylphenyl, 3,4-dihaloalkylphenyl, 2,5-dihaloalkylphenyl, 3,5-dihaloalkylphenyl, 2,6-dihaloalkylphenyl, 2-alkoxyphenyl, 3-alkoxypheny, 4-alkoxyphenyl, 2,3-dialkoxyphenyl, 2,4-dialkoxyphenyl, 3,4-dialkoxyphenyl, 3,5-dialkoxyphenyl, 2,5-dialkoxyphenyl, 2,6-dialkoxyphenyl, 2-alkylphenyl, 3-alkylphenyl, 4-alkylphenyl, 2,3-dialkylphenyl, 2,4-dialkylphenyl, 3,4-dialkylphenyl, 3,5-dialkylphenyl, 2,5-dialkylphenyl, and 2,6-dialkylphenyl.

11. The compound of claim 9, wherein R^2 is naphthalene-1-yl or napthalene-2-yl.

12. The compound of claim 7, wherein n is 0.

13. The compound of claim 7, wherein R^3 and R^4 are hydrogen.

14. The compound of claim 4, wherein R^5 is of the formula:



and R^6, R^7, R^8, R^9 and R^{10} are as defined in claim 1.

15. The compound of claim 14, wherein R^6, R^7, R^8, R^9 and R^{10} are hydrogen.

16. The compound of claim 14, wherein R^6, R^7, R^8 and R^9 are hydrogen and R^{10} is alkyl.

17. The compound of claim 5, wherein p is 1 and R^c and R^d are hydrogen.

18. The compound of claim 17, wherein R^2 is aryl.

19. The compound of claim 18, wherein R^2 is optionally substituted phenyl.

20. The compound of claim 19, wherein R^2 is optionally substituted naphthalenyl.

21. The compound of claim 19, wherein R^2 is selected from the group consisting of phenyl, 2-halophenyl, 3-halopheny, 4-halophenyl, 2,3-dihalophenyl, 2,4-dihalophenyl, 3,4-dihalophenyl, 2,5-dihalophenyl, 3,5-dihalophenyl, 2,6-dihalophenyl, 2-haloalkylphenyl, 3-haloalkylpheny, 4-haloalkylphenyl, 2,3-dihaloalkylphenyl, 2,4-dihaloalkylphenyl, 3,4-dihaloalkylphenyl, 2,5-dihaloalkylphenyl, 3,5-dihaloalkylphenyl, 2,6-dihaloalkylphenyl, 2-alkoxyphenyl, 3-alkoxypheny, 4-alkoxyphenyl, 2,3-dialkoxyphenyl, 2,4-dialkoxyphenyl, 3,4-dialkoxyphenyl, 3,5-dialkoxyphenyl, 2,5-dialkoxyphenyl, 2,6-dialkoxyphenyl, 2-alkylphenyl, 3-

alkylphenyl, 4-alkylphenyl, 2,3-dialkylphenyl, 2,4-dialkylphenyl, 3,4-dialkylphenyl, 3,5-dialkylphenyl, 2,5-dialkylphenyl, and 2,6-dialkylphenyl.

22. The compound of claim 20, wherein R^2 is naphthalene-1-yl or napthalene-2-yl.

23. The compound of claim 5, wherein n is 0.

24. The compound of claim 5, wherein R^3 and R^4 are hydrogen.

25. The compound of claim 5, wherein R^5 is of the formula:



and R^6, R^7, R^8, R^9 and R^{10} are as defined in claim 1.

26. The compound of claim 25, wherein R^6, R^7, R^8, R^9 and R^{10} are hydrogen.

27. The compound of claim 25, wherein R^6, R^7, R^8 and R^9 are hydrogen and R^{10} is alkyl.

28. The compound of claim 1, wherein said compound is of the formula:



,

and wherein n, r, X, Y, Z, R^1, R^2, R^3, R^4, R^6, R^7, R^8, R^9 and R^{10} are as defined in claim 1.

29. The compound of claim 1, wherein said compound is of the formula:



,

and wherein n, R^1, R^2, R^3, R^4, R^6, R^7, R^8, R^9, R^{10}, R^a and R^b are as defined in claim 1.

30. The compound of claim 1, wherein said compound is of the formula:



,

and wherein n, R^1, R^2, R^3, R^4, R^6, R^7, R^8, R^9, R^{10}, R^c and R^d are as defined in claim 1.

31. The compound of claim 1, wherein said compound is selected from the group consisting of:

2-benzenesulfonyl-5-piperazin-1-yl-1,2,3,4-tetrahydroisoquinoline;

2-benzenesulfonyl-5-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydroisoquinoline;

2-(4-fluoro-benzenesulfonyl)-5-piperazin-1-yl-1,2,3,4-tetrahydroisoquinoline;

2-(4-methoxy-benzenesulfonyl)-5-piperazin-1-yl-1,2,3,4-tetrahydroisoquinoline;

2-(3-fluoro-benzenesulfonyl)-5-piperazin-1-yl-1,2,3,4-tetrahydroisoquinoline;

2-(3,5-dichloro-benzenesulfonyl)-5-piperazin-1-yl-1,2,3,4-tetrahydroisoquinoline;

2-(3,5-bis-trifluoromethyl-benzenesulfonyl)-5-piperazin-1-yl-1,2,3,4-tetrahydroisoquinoline;

2-(2,5-dimethoxy-benzenesulfonyl)-5-piperazin-1-yl-1,2,3,4-tetrahydroisoquinoline;

2-(3-chloro-4-fluoro-benzenesulfonyl)-5-piperazin-1-yl-1,2,3,4-tetrahydroisoquinoline;

2-(2-fluoro-benzenesulfonyl)-5-piperazin-1-yl-1,2,3,4-tetrahydroisoquinoline;

2-(2-chloro-benzenesulfonyl)-5-piperazin-1-yl-1,2,3,4-tetrahydroisoquinoline;

2-(3-chloro-benzenesulfonyl)-5-piperazin-1-yl-1,2,3,4-tetrahydroisoquinoline;

2-(3-methyl-benzenesulfonyl)-5-piperazin-1-yl-1,2,3,4-tetrahydroisoquinoline;

2-(2,3-dichloro-benzenesulfonyl)-5-piperazin-1-yl-1,2,3,4-tetrahydroisoquinoline;

2-(2-chloro-4-fluoro-benzenesulfonyl)-5-piperazin-1-yl-1,2,3,4-tetrahydroisoquinoline;

2-(2,5-dichloro-benzenesulfonyl)-5-piperazin-1-yl-1,2,3,4-tetrahydroisoquinoline;

2-(naphthalene-1-sulfonyl)-5-piperazin-1-yl-1,2,3,4-tetrahydroisoquinoline;

2-(naphthalene-2-sulfonyl)-5-piperazin-1-yl-1,2,3,4-tetrahydroisoquinoline;

2-benzyl-5-piperazin-1-yl-3,4-dihydro-2*H*-isoquinolin-1-one;

2-benzyl-5-(4-ethyl-piperazin-1-yl)-3,4-dihydro-2*H*-isoquinolin-1-one;

2-(2-Methanesulfonyl-benzenesulfonyl)-5-piperazin-1-yl-1,2,3,4-tetrahydro-isoquinoline;

3-(5-Piperazin-1-yl-3,4-dihydro-1H-isoquinoline-2-sulfonyl)-benzamide;

[2-(5-Piperazin-1-yl-3,4-dihydro-1H-isoquinoline-2-sulfonyl)-phenyl]-urea; and

8-(5-Piperazin-1-yl-3,4-dihydro-1H-isoquinoline-2-sulfonyl)-quinoline.

32. A pharmaceutical composition comprising an effective amount of at least one compound of claim 1 in admixture with a pharmaceutically acceptable carrier.

33. A method for treating a central nervous system disease state in a subject, said method comprising administering to said subject a therapeutically effective amount of a compound of the formula:



I

or a pharmaceutically acceptable salt or prodrug thereof,

wherein:

n is from 0 to 3;

X is $-CR^aR^b-$ or $-C(O)-$, wherein R^a and R^b each independently are hydrogen or alkyl;

---- is an optional bond;

Y is $-SO_2-$ when X is $-CR^aR^b-$ and Y is $-(CR^cR^d)_p-$ when X is $-C(O)-$, wherein p is from 1 to 3 and R^c and R^d each independently are hydrogen or alkyl;

each R^1 independently is halo, alkyl, haloalkyl, heteroalkyl, hydroxy, nitro, alkoxy, cyano, $-S(O)_q-R^e$, $-NR^eR^f$, $-C(=O)-NR^eR^f$, $-SO_2-NR^eR^f$, $-N(R^e)-C(=O)-R^f$, or $-C(=O)R^e$, wherein q is from 0 to 2 and R^e and R^f each independently are hydrogen or alkyl;

R^2 is aryl, heteroaryl or cycloalkyl;

R^3 and R^4 each independently are hydrogen or alkyl; and

R^5 is of the formula:



wherein:

Z is –N– or –CH–;

r is from 1 to 3; and

R^6, R^7, R^8, R^9 and R^{10} each independently are hydrogen or alkyl.

34. The method of Claim 33, wherein the disease state is selected from psychoses, schizophrenia, manic depressions, neurological disorders, memory disorders, attention deficit disorder, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease and Huntington's disease.

35. A method for treating a disorder of the gastrointestinal tract in a subject, said method comprising administering to said subject a therapeutically effective amount of a compound of the formula:



I

or a pharmaceutically acceptable salt or prodrug thereof,

wherein:

n is from 0 to 3;

X is $-CR^aR^b-$ or $-C(O)-$, wherein R^a and R^b each independently are hydrogen or alkyl;

---- is an optional bond;

Y is $-SO_2-$ when X is $-CR^aR^b-$ and Y is $-(CR^cR^d)_p-$ when X is $-C(O)-$, wherein p is from 1 to 3 and R^c and R^d each independently are hydrogen or alkyl;

each R^1 independently is halo, alkyl, haloalkyl, heteroalkyl, hydroxy, nitro, alkoxy, cyano, $-S(O)_q-R^e$, $-NR^eR^f$, $-C(=O)-NR^eR^f$, $-SO_2-NR^eR^f$, $-N(R^e)-C(=O)-R^f$, or $-C(=O)R^e$, wherein q is from 0 to 2 and R^e and R^f each independently are hydrogen or alkyl;

R^2 is aryl, heteroaryl or cycloalkyl;

R^3 and R^4 each independently are hydrogen or alkyl; and

R^5 is of the formula:



wherein:

Z is –N– or –CH–;

r is from 1 to 3; and

R^6, R^7, R^8, R^9 and R^{10} each independently are hydrogen or alkyl.

36. A method for producing a substituted isoquinoline compound, said method comprising:

reacting a compound of the formula:



wherein:

n is from 0 to 3;

each R^1 independently is halo, alkyl, haloalkyl, heteroalkyl, hydroxy, nitro, alkoxy, cyano, $-S(O)_q-R^e$, $-NR^eR^f$, $-C(=O)-NR^eR^f$, $-SO_2-NR^eR^f$, $-N(R^e)-C(=O)-R^f$, or $-C(=O)R^e$, wherein q is from 0 to 2 and R^e and R^f each independently are hydrogen or alkyl;

R^a, R^3 and R^4 each independently are hydrogen or alkyl;

---- is an optional bond;

R^5 is 5- or 6- position of the isoquinoline ring system and is of the formula:



wherein:

r is from 1 to 3;

Z is –N– or –CH–; and

R^6, R^7, R^8, R^9 and R^{10} each independently are hydrogen or alkyl;

with a sulfonyl halide of the formula: R^2-S0_2-G wherein R^2 is aryl, heteroaryl or cycloalkyl and G is halo;

to yield a compound of the formula: